Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection

Pediatric Pulmonology

Volumn 42, Issue 11, 2007, Pages 1008-1017

  Moriarty, T F ^a   McElnay, J C ^a   Elborn, J S ^a   Tunney, M M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Ceftazidime; Cystic fibrosis; Pharmacodynamic indices; Pulmonary infection; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD SAMPLING; BURKHOLDERIA CEPACIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; SPUTUM CULTURE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CEFTAZIDIME; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS INFECTIONS; SPUTUM; TOBRAMYCIN;

EID: 36248992414     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20671     Document Type: Article

References (47)

1. den Hollander JG, Horrevorts AM, van Goor ML, Verbrugh HA, Mouton JW. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1997;41:95-100.
2. Cazzola M, Blasi F, Terzano C, Matera MG, Marsico SA. Delivering antibacterials to the lungs: Considerations for optimizing outcomes. Am J Respir Med 2002;1:261-272.
3. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-629.
4. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
5. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765.
6. Kashuba AD, Bertino JS, Jr., Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998;42:1842-1844.
7. Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;23:1231-1244.
8. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-847.
9. Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999;43:2473-2478.
10. Bastone EB, Li SC, Ioannides-Demos LL, Spicer WJ, McLean AJ. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother 1993;37:914-917.
11. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-556.
12. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
13. Smith AL, Doershuk C, Goldmann D, Gore E, Human B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, Williams-Warren J, Wilmott R, Wilson HD, Yogev R. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134:413-421.
14. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 2003;123:1495-1502.
15. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P, Bell S, Chan F, Rose B, Jeanneret A, Stephenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial Lancet 2005;366:463-471.
16. Turner A, Pedler SJ, Carswell F, Spencer GR, Speller DC. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother 1984;14:521-527.
17. Isoherranen N, Soback S. Determination of gentamicins C(1), C(1a), and C(2) in plasma and urine by HPLC. Clin Chem 2000;46:837-842.
18. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48:5-16.
19. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-130.
20. Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990;34:2307-2311.
21. Gordon RC, Regamey C, Kirby WM. Serum protein binding of the aminoglycoside antibiotics. Antimicrob Agents Chemother 1972;2:214-216.
22. Ullmann U. The protein binding of ticarcillin and tobramycin. J Antimicrob Chemother 1976;2:213-214.
23. Azoulay-Dupuis E, Vallee E, Bedos JP, Muffat-Joly M, Pocidalo JJ. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 1991;35:1024-1028.
24. Maesen FP, Costongs R, Davies BI. Concentrations of Cefixime in bronchial mucosa and sputum. Thorax 1990;45:982-983.
25. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: In vivo observations and clinical relevance. Antimicrob Agents Chemother 1992;36:1176-1180.
26. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C. Efficacy tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998;78:536-539.
27. Klekner A, Bagyi K, Bognar L, Gaspar A, Andrasi M, Szabo J. Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia. J Clin Microbiol 2006;44:3418-3421.
28. Lovering AM, Pycock CJ, Harvey JE, Reeves DS. The pharmacokinetics and sputum penetration of ampicillin and amoxycillin following simultaneous i.v. administration. J Antimicrob Chemother 1990;25:385-392.
29. Cazzola M, Matera MG, Donnarumma G, Tufano MA, Sanduzzi A, Marchetti F, Blast F. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005;128:2093-2098.
30. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002;50:553-559.
31. Vinks AA, Touw DJ, Heijerman HG, Danhof M, de Leede GP, Bakker W. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994;16:341-348.
32. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997;40:125-133.
33. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001;48:325-327.
34. Paradis D, Vallee F, Allard S, Bisson C, Daviau N, Drapeau C, Auger F, LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992;36:2085-2092.
35. Alexander MR, Berglund EM, Kasik JE, Fox A, Chinn WM. The concentration of tobramycin in bronchial secretions. Chest 1979;75:675-678.
36. Conte JE, Jr., Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-529.
37. Mombelli G, Coppens L, Thys JP, Klastersky J. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother 1981;19:72-75.
38. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43:2877-2880.
39. UK CF Trust Antibiotic Group. Antibiotic treatment for cystic fibrosis. London: Cystic Fibrosis Trust, 2002. pp 1-74.
40. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000;16:749-767.
41. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007.
42. Al-Aloul M, Miller H, Stockton P, Ledson MJ, Walshaw MJ. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005;4:197-201.
43. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20.
44. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123:28-36.
45. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-279.
46. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-480.
47. Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: Comparative effects of helium and nitrogen. Anesthesiology 2005;102:995-1000.